After all that effort with alpha-blockers, beta-blockers, ACE inhibitors, etc….are we just going to circle back to diuretics??
Will Eli Lilly fork over $1,000,000,000 to make Zyprexa marketing headaches go away?
Bayer‘s Nexavar – looking promising for leukemia (AML).
Novartis‘ Galvus gets approval in EU. This diabetes treatment (similar to Merck‘s Januvia) has had problems getting marketing clearance in the U.S. – it’ll be interesting to track its safety record in Europe in coming years.
Pfizer‘s anti-smoking drug Chantix gets a stronger warning for psychiatric side effects.
BREAKING NEWS: Amgen and Takeda announce major deal to collaborate on pipeline biotech drugs.